Log In
Print this Print this

Biosimilar rituximab (MabionCD20)

  Manage Alerts
Collapse Summary General Information
Company Mabion S.A.
DescriptionBiosimilar of rituximab, a chimeric mAb against CD20 antigen
Molecular Target CD20
Mechanism of ActionBinds CD20; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today